Hepatic encephalopathy (HE) is the leading cause of mortality in patients suffering from acute liver failure and also in those patients suffering from liver cirrhosis and associated with end stage liver disease. A person suffering from hepatic encephalopathy loses the ability to metabolize ammonia, which results in the buildup of ammonia in various tissues and organs of the body. Moreover, ammonia crosses the blood–brain barrier, and thus causing neurocognitive impairment. Hepatic encephalopathy can be classified into two types: covert hepatic encephalopathy (CHE) and overt hepatic encephalopathy (OHE), out of which, overt hepatic encephalopathy is associated with high rates of mortality and poor quality of life, as compared to covert hepatic encephalopathy (CHET). The major market participants have developed novel technologies and techniques for treating liver disorders. The market will expand as a result in the coming year.
Increase in the government and non-government organizations initiatives to improve access to affordable liver related treatment option. Rise in the awareness regarding the importance of liver health among the people and favorable reimbursement are the factors likely drive the market growth. For instance, in October 2022, Bausch Health Companies Inc., and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies announced the endorsement of the implementation of K76.82, an ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE), a complication of cirrhosis that affects the brain
Key features of the study:
- This report provides in-depth analysis of the global hepatic encephalopathy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global hepatic encephalopathy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include ASKER Pharmaceutical Co., Ltd, Cosmo Pharmaceuticals N.V, Lupin Limited, Kaleido Biosciences, Kannalife Sciences Inc., Bausch Health Companies Inc, Ferring Pharmaceuticals In, Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V, Abbott Laboratories, QR Science and Technology Development Co.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global hepatic encephalopathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hepatic encephalopathy market
Detailed Segmentation:
- Global Hepatic Encephalopathy Market, By Drug Class:
- Antibiotics
- Laxatives
- L-ornithine L-aspartate
- Others
- Global Hepatic Encephalopathy Market, By Route of administration:
- Global Hepatic Encephalopathy Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Hepatic Encephalopathy Market, By Region:
- North America
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- ASKA Pharmaceutical Co., Ltd.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cosmo Pharmaceuticals N.V
- Lupin Limited
- Kaleido Biosciences
- Kannalife Sciences Inc.
- Bausch Health Companies Inc.
- Ferring Pharmaceuticals Inc.
- Mallinckrodt Pharmaceuticals
- Umecrine Cognition AB
- Norgine B.V
- Abbott Laboratories
- Kos Pharmaceuticals, Inc.
- QR Science and Technology Development Co.
“*” marked represents similar segmentation in other categories in the respective section.
